Tyler Dylan-hyde
Chief Legal Officer
Pharmaceuticals
CRISPR Therapeutics
Switzerland
Biography
Dr. Tyler Dylan-Hyde has more than two decades of experience both in law firms and in-house for privately-held and public companies developing gene-based therapeutics and other technologies. Tyler was a Partner at Morrison & Foerster LLP, specializing in the development and defense of global IP portfolios, licensing and corporate transactions. As in-house general counsel, he helped lead Collateral Therapeutics, which had an IPO on NASDAQ and was later acquired by Schering AG (now Bayer Healthcare Pharmaceuticals), InnerCool Therapies, which was advanced through FDA clearance and acquired by Philips Healthcare, and Cardium Therapeutics, which developed a portfolio of companies, some acquired and others currently in partnership. Tyler received his B.Sc. in cell, molecular and developmental biology from McGill University, Montreal, Canada, his Ph.D. in biology from the University of California, San Diego, and his J.D. from the University of California, Berkley (Boalt Hall School of Law). He is a co-inventor of several patent applications and a co-author of a number of scientific publications.
Research Interest
Pharmaceutical Sciences
